Adenylyl Cyclase 9 Polymorphisms Reveal Potential Link to HDL Function and Cardiovascular Events in Multiple...

Area of Science:

• Biochemistry
• Cardiovascular Science
• Genetics

Background:

• Adenylyl cyclase 9 (ADCY9) mediates β2-adrenoceptor (β2-AR) signaling, with both proteins linked to cholesterol-rich caveolae.
• Apolipoprotein A1 (ApoA1), a component of high-density lipoprotein (HDL), influences membrane cholesterol and potentially β2-AR signaling.
• Sickle Cell Disease (SCD) patients often have low HDL/ApoA1, and β2-AR activation can trigger vaso-occlusive events; ADCY9 polymorphism is linked to stroke risk in SCD.

Purpose of the Study:

• To hypothesize a common mechanism linking HDL/ApoA1 interactions with ADCY9 and β2-AR signaling in cardiovascular risk.
• To highlight the need for characterizing genetic polymorphisms influencing HDL-raising therapies in non-Caucasian SCD patients.

Main Methods:

• Review of existing literature on ADCY9, β2-AR signaling, HDL, ApoA1, and their roles in SCD and cardiovascular disease.
• Analysis of clinical trial data regarding ADCY9 polymorphism and cardiovascular event risk in relation to HDL-raising compounds.
• In vitro studies demonstrating cholesterol's modulation of β2-AR signaling.

Main Results:

• ADCY9 polymorphism is a risk factor for stroke in SCD and cardiovascular events in Caucasian patients treated with HDL-raising drugs.
• In vitro data suggest cholesterol levels influence β2-AR signaling.
• Disparate observations in SCD and cardiovascular risk may share a common mechanistic link involving HDL/ApoA1 and ADCY9 on β2-AR signaling.

Conclusions:

• A unified mechanism involving HDL/ApoA1, ADCY9, and β2-AR signaling is proposed to explain cardiovascular risk in SCD.
• Personalized cardiovascular treatments may be facilitated by understanding genetic polymorphisms in diverse populations, particularly those with SCD.